Vorapaxar | Uses, Brand Names, Mechanism Of Action
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study - ScienceDirect
Vorapaxar - Wikipedia
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease - Justin T. Morrison, Nicholas Govsyeyev, Connie N. Hess, Marc P. Bonaca, 2022
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
Late Breaking Clinical Trials: CORONARY (On-Pump vs. Off-Pump CABG), CPORT (Nonprimary PCI Without Surgical Backup), ASCERT (CABG vs. PCI), and TRAP2-TIMI 50 (Vorapaxar for... | tctmd.com
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
The net clinical benefit of vorapaxar (CV death, MI, stroke or GUSTO... | Download Scientific Diagram
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes | NEJM
Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events - Clinical Trials Arena
TRA 2°P-TIMI 50 – TIMI STUDY GROUP
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
IJMS | Free Full-Text | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction | tctmd.com
Vorapaxar - Wikipedia
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
![PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c4d402004bb1cd7f7142aa35447751937911b5ff/2-Figure1-1.png "PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar")
PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar
